TGFB1 and breast carcinoma: Given that key stemness-related pathways—such as Wnt/β-catenin, TGF-β, and STAT3—are conserved across various tumor types, including colorectal and breast cancers (44–46), we conducted an in vivo study of stemness inhibitors using the EO771 triple-negative breast cancer mouse model.